RASSF1A: Not a prototypical Ras effector

Small GTPases

Volumn 2, Issue 3, 2011, Pages 1-10

  Gordon, Marilyn ^a   Baksh, Shairaz ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

14 3 3; Apoptosis; Microtubule; Mitosis; MOAP 1; Ras; RASSF1A; Tumor suppressor gene

Indexed keywords

RAS ASSOCIATION DOMAIN FAMILY PROTEIN 10; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 5A; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 7; RAS PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; COSTELLO SYNDROME; ENDOPLASMIC RETICULUM; GENETIC POLYMORPHISM; HUMAN; LEOPARD SYNDROME; LUNG CANCER; MELANOMA; NEUROFIBROMATOSIS; NONHUMAN; NOONAN SYNDROME; PANCREAS CANCER; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN METHYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 79958844464     PISSN: 21541248     EISSN: 21541256     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Warne PH, Viciana PR, Downward J. Direct interaction of Ras and the amino-terminal region of Raf-1 in vitro. Nature 1993; 364:352-5; PMID: 8332195; DOI:10.1038/364352a0.
2. Buday L, Downward J. Many faces of Ras activation. Biochim Biophys Acta 2008; 1786:178-87.
3. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009; 19:230-6; PMID: 19467855; DOI:10.1016/j.gde.2009.04.001.
4. Bentires-Alj M, Kontaridis MI, Neel BG. Stops along the RAS pathway in human genetic disease. Nat Med 2006; 12:283-5; PMID: 16520774; DOI:10.1038/nm0306-283.
5. Grossmann KS, Rosario M, Birchmeier C, Birchmeier W. The tyrosine phosphatase Shp2 in development and cancer. Adv Cancer Res 2010; 106:53-89; PMID: 20399956; DOI:10.1016/S0065-230X(10)06002-1.
6. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999; 400:468-72; PMID: 10440378; DOI:10.1038/22788.
7. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998; 8:49-54; PMID: 9529605; DOI:10.1016/S0959-437X(98)80061-0.
8. Cox AD, Der CJ. The dark side of Ras: regulation of apoptosis. Oncogene 2003; 22:8999-9006; PMID: 14663478; DOI:10.1038/sj.onc.1207111.
9. Terada K, Kaziro Y, Satoh T. Analysis of Rasdependent signals that prevent caspase-3 activation and apoptosis induced by cytokine deprivation in hematopoietic cells. Biochem Biophys Res Commun 2000; 267:449-55; PMID: 10623640; DOI:10.1006/bbrc.1999.1955.
10. Tsuneoka M, Mekada E. Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras. Oncogene 2000; 19:115-23; PMID: 10644986; DOI:10.1038/sj.onc.1203232.
11. Gómez J, Martinez C, Fernandez B, Garcia A, Rebollo A. Ras activation leads to cell proliferation or apoptotic cell death upon interleukin-2 stimulation or lymphokine deprivation, respectively. Eur J Immunol 1997; 27:1610-8; PMID: 9247568; DOI:10.1002/eji.1830270704.
12. Latinis KM, Carr LL, Peterson EJ, Norian LA, Eliason SL, Koretzky GA. Regulation of CD95 (Fas) ligand expression by TCR-mediated signaling events. J Immunol 1997; 158:4602-11; PMID: 9144472.
13. Sherwood V, Recino A, Jeffries A, Ward A, Chalmers AD. The N-terminal RASSF family: a new group of Ras-association-domain-containing proteins, with emerging links to cancer formation. Biochem J 2010; 425:303-11; PMID: 20025613; DOI:10.1042/BJ20091318.
14. Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796:114-28; PMID: 19344752; DOI:10.1016/j. bbcan.2009.03.004.
15. Fujita H, Fukuhara S, Sakurai A, Yamagishi A, Kamioka Y, Nakaoka Y, et al. Local activation of Rap1 contributes to directional vascular endothelial cell migration accompanied by extension of microtubules on which RAPL, a Rap1-associating molecule, localizes. J Biol Chem 2005; 280:5022-31; PMID: 15569673; DOI:10.1074/jbc.M409701200.
16. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, Zhang Xf X, Dammann R, Pfeifer GP, et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002; 21:1381-90; PMID: 11857081; DOI:10.1038/sj.onc.1205192.
17. Rodriguez-Viciana P, Sabatier C, McCormick F. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 2004; 24:4943-54; PMID: 15143186; DOI:10.1128/MCB.24.11.4943-4954.2004.
18. Foley CJ, Freedman H, Choo SL, Onyskiw C, Fu NY, Yu VC, et al. Dynamics of RASSF1A/MOAP-1 association with death receptors. Mol Cell Biol 2008; 28:4520-35; PMID: 18474619; DOI:10.1128/MCB.02011-07.
19. Hamilton G, Yee KS, Scrace S, O'Neill E. ATM regulates a RASSF1A-dependent DNA damage response. Curr Biol 2009; 19:2020-5; PMID: 19962312; DOI:10.1016/j.cub.2009.10.040.
20. Avruch J, Xavier R, Bardeesy N, Zhang XF, Praskova M, Zhou D, et al. Rassf family of tumor suppressor polypeptides. J Biol Chem 2009; 284:11001-5; PMID: 19091744; DOI:10.1074/jbc.R800073200.
21. Harjes E, Harjes S, Wohlgemuth S, Muller KH, Krieger E, Herrmann C, et al. GTP-Ras disrupts the intramolecular complex of C1 and RA domains of Nore1. Structure 2006; 14:881-8; PMID: 16698549; DOI:10.1016/j.str.2006.03.008.
22. Stieglitz B, Bee C, Schwarz D, Yildiz O, Moshnikova A, Khokhlatchev A, et al. Novel type of Ras effector interaction established between tumour suppressor NORE1A and Ras switch II. EMBO J 2008; 27:1995-2005; PMID: 18596699; DOI:10.1038/emboj.2008.125.
23. Vos MD, Martinez A, Ellis CA, Vallecorsa T, Clark GJ. The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J Biol Chem 2003; 278:21938-43; PMID: 12676952; DOI:10.1074/jbc.M211019200.
24. Park J, Kang SI, Lee SY, Zhang XF, Kim MS, Beers LF, et al. Tumor suppressor Ras-association domain family 5 (RASSF5/NORE1) mediates death receptor ligand-induced apoptosis. J Biol Chem 2010; 285:35029-38; PMID: 20810663; DOI:10.1074/jbc. M110.165506.
25. Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19:491-505; PMID: 20951342; DOI:10.1016/j.devcel.2010.09.011.
26. Delpire E. The mammalian family of sterile 20p-like protein kinases. Pflugers Arch 2009; 458:953-67; PMID: 19399514; DOI:10.1007/s00424-009-0674-y.
27. Praskova M, Khoklatchev A, Ortiz-Vega S, Avruch J. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem J 2004; 381:453-62; PMID: 15109305; DOI:10.1042/BJ20040025.
28. Ura S, Nishina H, Gotoh Y, Katada T. Activation of the c-Jun N-terminal kinase pathway by MST1 is essential and sufficient for the induction of chromatin condensation during apoptosis. Mol Cell Biol 2007; 27:5514-22; PMID: 17548476; DOI:10.1128/MCB.00199-07.
29. Halder G, Johnson RL. Hippo signaling: growth control and beyond. Development 2011; 138:9-22; PMID: 21138973; DOI:10.1242/dev.045500.
30. Aoyama Y, Avruch J, Zhang XF. Nore1 inhibits tumor cell growth independent of Ras or the MST1/2 kinases. Oncogene 2004; 23:3426-33; PMID: 15007383; DOI:10.1038/sj.onc.1207486.
31. Oh HJ, Lee KK, Song SJ, Jin MS, Song MS, Lee JH, et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 2006; 66:2562-9; PMID: 16510573; DOI:10.1158/0008-5472.CAN-05-2951.
32. Ikeda M, Hirabayashi S, Fujiwara N, Mori H, Kawata A, Iida J, et al. Ras-association domain family protein 6 induces apoptosis via both caspasedependent and caspase-independent pathways. Exp Cell Res 2007; 313:1484-95; PMID: 17367779; DOI:10.1016/j.yexcr.2007.02.013.
33. Avruch J, Zhou D, Fitamant J, Bardeesy N. Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br J Cancer 2011; 104:24-32; PMID: 21102585; DOI:10.1038/sj.bjc.6606011.
34. Del Re DP, Matsuda T, Zhai P, Gao S, Clark GJ, Van Der Weyden L, et al. Proapoptotic Rassf1A/Mst1 signaling in cardiac fibroblasts is protective against pressure overload in mice. J Clin Invest 2010; 120:3555-67; PMID: 20890045; DOI:10.1172/JCI43569.
35. Densham RM, O'Neill E, Munro J, Konig I, Anderson K, Kolch W, et al. MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to regulate p21Waf1/Cip1 stability. Mol Cell Biol 2009; 29:6380-90; PMID: 19822666; DOI:10.1128/MCB.00116-09.
36. Kim D, Shu S, Coppola MD, Kaneko S, Yuan ZQ, Cheng JQ. Regulation of proapoptotic mammalian ste20-like kinase MST2 by the IGF1-Akt pathway. PLoS ONE 2010; 5:e9616; PMID: 20231902; DOI:10.1371/journal.pone.0009616.
37. Oh S, Lee D, Kim T, Kim TS, Oh HJ, Hwang CY, et al. Crucial role for Mst1 and Mst2 kinases in early embryonic development of the mouse. Mol Cell Biol 2009; 29:6309-20; PMID: 19786569; DOI:10.1128/MCB.00551-09.
38. Baksh S, Tommasi S, Fenton S, Yu VC, Martins LM, Pfeifer GP, et al. The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol Cell 2005; 18:637-50; PMID: 15949439; DOI:10.1016/j. molcel.2005.05.010.
39. Ghazaleh HA, Chow RS, Choo SL, Pham D, Olesen JD, Wong RX, et al. 14-3-3 mediated regulation of the tumor suppressor protein, RASSF1A. Apoptosis 2010; 15:117-27; PMID: 20069457; DOI:10.1007/s10495-009-0451-6.
40. Vos MD, Dallol A, Eckfeld K, Allen NP, Donninger H, Hesson LB, et al. The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem 2006; 281:4557-63; PMID: 16344548; DOI:10.1074/jbc. M512128200.
41. Rosenquist M. 14-3-3 proteins in apoptosis. Braz J Med Biol Res 2003; 36:403-8; PMID: 12700817; DOI:10.1590/S0100-879X2003000400001.
42. Molzan M, Schumacher B, Ottmann C, Baljuls A, Polzien L, Weyand M, et al. Impaired binding of 14-3-3 to C-RAF in Noonan syndrome suggests new approaches in diseases with increased Ras signaling. Mol Cell Biol 2010; 30:4698-711; PMID: 20679480; DOI:10.1128/MCB.01636-09.
43. Rushworth LK, Hindley AD, O'Neill E, Kolch W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol 2006; 26:2262-72; PMID: 16508002; DOI:10.1128/MCB.26.6.2262-2272.2006.
44. Wu D, Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci 2010; 35:161-8; PMID: 19884009; DOI:10.1016/j.tibs.2009.10.002.
45. Verma SK, Ganesan TS, Parker PJ. The tumour suppressor RASSF1A is a novel substrate of PKC. FEBS Lett 2008; 582:2270-6; PMID: 18514071; DOI:10.1016/j.febslet.2008.05.028.
46. Rong R, Jiang LY, Sheikh MS, Huang Y. Mitotic kinase Aurora-A phosphorylates RASSF1A and modulates RASSF1A-mediated microtubule interaction and M-phase cell cycle regulation. Oncogene 2007; 26:7700-8; PMID: 17563743; DOI:10.1038/sj.onc.1210575.
47. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, et al. The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 2005; 20:645-63; PMID: 15736067.
48. Dallol A, Agathanggelou A, Fenton SL, Ahmed-Choudhury J, Hesson L, Vos MD, et al. RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res 2004; 64:4112-6; PMID: 15205320; DOI:10.1158/0008-5472.CAN-04-0267.
49. El-Kalla M, Onyskiw C, Baksh S. Functional importance of RASSF1A microtubule localization and polymorphisms. Oncogene 2010; 29:5729-40; PMID: 20697344; DOI:10.1038/onc.2010.316.
50. Shivakumar L, Minna J, Sakamaki T, Pestell R, White MA. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 2002; 22:4309-18; PMID: 12024041; DOI:10.1128/MCB.22.12.4309-4318.2002.
51. Oceandy D, Pickard A, Prehar S, Zi M, Mohamed TM, Stanley PJ, et al. Tumor suppressor Rasassociation domain family 1 isoform A is a novel regulator of cardiac hypertrophy. Circulation 2009; 120:607-16; PMID: 19652091; DOI:10.1161/CIRCULATIONAHA.109.868554.
52. Dallol A, Cooper WN, Al-Mulla F, Agathanggelou A, Maher ER, Latif F. Depletion of the Ras association domain family 1, isoform A-associated novel microtubule-associated protein, C19ORF5/MAP1S, causes mitotic abnormalities. Cancer Res 2007; 67:492-500; PMID: 17234756; DOI:10.1158/0008-5472.CAN-06-3604.
53. Liu L, Xie R, Yang C, McKeehan WL. Dual function microtubule-and mitochondria-associated proteins mediate mitotic cell death. Cell Oncol 2009; 31:393-405; PMID: 19759419.
54. Liu L, Vo A, Liu G, McKeehan WL. Putative tumor suppressor RASSF1 interactive protein and cell death inducer C19ORF5 is a DNA binding protein. Biochem Biophys Res Commun 2005; 332:670-6; PMID: 15907802; DOI:10.1016/j. bbrc.2005.05.006.
55. Xie R, Nguyen S, McKeehan K, Wang F, McKeehan WL, Liu L. Microtubule-associated protein 1s (MAP1S) bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation. J Biol Chem 2011; 286:10367-77; PMID: 21262964; DOI:10.1074/jbc. M110.206532.
56. Vos MD, Ellis CA, Bell A, Birrer MJ, Clark GJ. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 2000; 275:35669-72; PMID: 10998413; DOI:10.1074/jbc. C000463200.
57. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007; 120:3163-72; PMID: 17878233; DOI:10.1242/jcs.010389.
58. Eckfeld K, Hesson L, Vos MD, Bieche I, Latif F, Clark GJ. RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res 2004; 64:8688-93; PMID: 15574778; DOI:10.1158/0008-5472.CAN-04-2065.
59. Allen NP, Donninger H, Vos MD, Eckfeld K, Hesson L, Gordon L, et al. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 2007; 26:6203-11; PMID: 17404571; DOI:10.1038/sj.onc.1210440.